Jennerian Pustular Psoriasis – A Comprehensive Medical Guide

Overview

Jennerian pustular psoriasis (also called generalized pustular psoriasis, GPP, or Von Zumbusch type) is a rare, severe form of psoriasis characterized by the sudden appearance of sterile, pus‑filled blisters (pustules) over large areas of the skin. Unlike the more common plaque psoriasis, Jennerian pustular psoriasis can develop rapidly, often accompanied by fever, chills, and systemic illness.

• Population affected: It can occur at any age, but there are two peaks—infancy/early childhood and adulthood (often after 40 years). Both sexes are equally affected.
• Prevalence: GPP accounts for 1–5 % of all psoriasis cases worldwide. In the United States the prevalence is estimated at ~0.02 % of the general population (≈70 000 people)【1】.
• Geographic variation: Higher incidence is reported in East Asian and Scandinavian populations, possibly reflecting genetic differences.

Symptoms

The clinical picture can evolve quickly, often within days. The hallmark is the presence of sterile pustules on a background of red, inflamed skin. Common associated features include systemic signs of inflammation.

Cutaneous manifestations

• Generalized pustules: Small (1–5 mm), non‑infectious vesicles filled with creamy‑white pus. They can coalesce into larger “lakes” of pus.
• Erythema: Diffuse redness surrounding the pustules; may cover the trunk, limbs, and face.
• Scaling:
  After pustules rupture, they leave a flaky, silvery scale reminiscent of classic plaque psoriasis.
• Nikolsky sign: The skin may shear off with gentle pressure—an indicator of epidermal instability.
• Target lesions: In some patients, lesions may mimic erythema multiforme.

Systemic signs

• Fever (often >38 °C)
• Chills and night sweats
• Generalized malaise, fatigue
• Headache, myalgias
• Elevated heart rate (tachycardia)

Laboratory abnormalities

• Leukocytosis with neutrophilia
• Elevated C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
• Electrolyte disturbances (hypocalcemia, hyponatremia) due to massive skin turnover
• Possible hepatic or renal dysfunction in severe cases

Causes and Risk Factors

The exact trigger for Jennerian pustular psoriasis remains incompletely understood, but it is believed to arise from a combination of genetic susceptibility and environmental triggers.

Genetic factors

• IL36RN mutations: Loss‑of‑function variants in the interleukin‑36 receptor antagonist gene are identified in 30‑40 % of sporadic GPP patients and up to 70 % in familial cases【2】.
• AP1S3, CARD14, and MPO mutations: Less common but associated with pustular phenotypes.

Environmental / iatrogenic triggers

• Sudden withdrawal of systemic corticosteroids or other immunosuppressants.
• Infections (bacterial, viral, fungal) that stimulate the immune system.
• Medications: lithium, β‑blockers, terbinafine, non‑steroidal anti‑inflammatory drugs (NSAIDs).
• Pregnancy (known as “impetigo herpetiformis” when it occurs in the third trimester).
• Severe emotional stress or extreme temperature changes.

Other risk factors

• History of plaque psoriasis (≈50 % of GPP patients have prior plaque disease).
• Family history of pustular psoriasis or other autoimmune diseases.
• Underlying metabolic disorders (e.g., obesity, diabetes) that heighten systemic inflammation.

Diagnosis

Accurate diagnosis relies on clinical assessment, laboratory work‑up, and sometimes skin biopsy to exclude infection.

Clinical evaluation

• Detailed history of symptom onset, prior psoriasis, medication changes, and family history.
• Full skin examination to document distribution and morphology of pustules.

Laboratory tests

• Complete blood count (CBC) – often shows neutrophilic leukocytosis.
• CRP & ESR – markers of systemic inflammation.
• Serum electrolytes, calcium, renal and liver panels – to detect metabolic derangements.
• Cultures (skin swab, blood) – performed to rule out secondary bacterial infection, especially if lesions are tender or purulent.

Skin biopsy

A 4‑mm punch biopsy from an active pustule typically shows subcorneal collections of neutrophils (Munro microabscesses) without bacterial organisms. Histology helps differentiate GPP from acute generalized exanthematous pustulosis (AGEP) and infectious pustulosis.

Genetic testing

Testing for IL36RN and related gene mutations can confirm a hereditary predisposition, guide counseling, and influence therapeutic choices (e.g., IL‑36 inhibitors).

Diagnostic criteria

The European Rare and Severe Psoriasis Group (ERASPEN) criteria require:

1. Acute onset of widespread sterile pustules on erythematous skin.
2. Accompanying systemic features (fever, leukocytosis).
3. Exclusion of infection, drug reaction, or other pustular dermatoses.

Treatment Options

Because Jennerian pustular psoriasis can be life‑threatening, rapid control of inflammation is essential. Therapy generally follows a stepwise approach: acute stabilization, transition to maintenance, and long‑term disease control.

1. Acute stabilization (hospital‑based)

• Systemic retinoids: Acitretin 25–50 mg/day is first‑line for many clinicians; it normalizes keratinocyte differentiation.
• Ciclosporin: 2.5–5 mg/kg/day (adjusted for renal function) provides rapid immunosuppression.
• Methotrexate: 15–25 mg weekly, often combined with folic acid, useful when retinoids are contraindicated.
• Biologic agents:
  • IL‑17 inhibitors (secukinumab, ixekizumab) – fast onset, FDA‑approved for GPP in 2022.
  • IL‑23 inhibitors (guselkumab, risankizumab) – effective for patients with concurrent plaque psoriasis.
  • IL‑36 receptor antagonist (spesolimab) – specifically approved for acute GPP flares (2021, EMA & FDA). Provides symptom relief within days.
• Supportive care: Intravenous fluids, electrolyte replacement, antipyretics, and wound care to prevent infection.

2. Transition to maintenance

• Low‑dose acitretin (10–25 mg) or methotrexate for long‑term control.
• Continuation of biologic therapy (IL‑17, IL‑23, or IL‑36 inhibitors) under dermatology supervision.
• Gradual tapering of systemic steroids (if used) to avoid rebound flares.

3. Lifestyle and adjunctive measures

• Skin moisturization: Thick, fragrance‑free emollients (e.g., petrolatum‑based ointments) reduce transepidermal water loss.
• Stress management: Mindfulness, yoga, or counseling; stress is a known trigger.
• Smoking cessation & alcohol moderation: Both exacerbate psoriatic inflammation.
• Weight control: Obesity is linked to higher biologic dosing needs and flare frequency.

Potential drug interactions & precautions

• Acitretin is teratogenic – effective contraception required for women of child‑bearing age for ≥3 years after discontinuation.
• Ciclosporin may cause nephrotoxicity; monitor creatinine and blood pressure.
• Biologics increase susceptibility to infections; screen for latent TB and hepatitis before initiation.

Living with Jennerian Pustular Psoriasis

Even after a flare resolves, vigilance is needed to prevent recurrence.

Daily skin care

1. Cleanse with lukewarm water and a mild, fragrance‑free cleanser; avoid scrubbing.
2. Apply a generous layer of barrier ointment (e.g., Aquaphor) within three minutes of bathing.
3. Use non‑adhesive dressings on areas prone to rupture to reduce secondary infection.

Monitoring & follow‑up

• Track flare triggers in a diary (medications, stress events, infections).
• Schedule dermatology visits every 3–6 months, or sooner if new symptoms appear.
• Routine labs every 3 months while on systemic therapy (CBC, liver/renal panels, lipids).

Psychosocial support

Severe skin disease can impact mental health. Consider:

• Referral to a psychologist or support group.
• Patient‑education resources from the National Psoriasis Foundation.
• Open communication with employers/schools about reasonable accommodations.

Practical tips for work and travel

• Carry a small “psoriasis kit” (clean wipes, emollient tube, sterile gauze).
• Stay hydrated; dry cabin air can worsen skin dryness.
• Plan ahead for medication storage—many biologics require refrigeration.

Prevention

While genetic predisposition cannot be altered, the risk of triggers can be minimized.

• Medication management: Never discontinue systemic steroids abruptly; taper under physician guidance.
• Infection control: Prompt treatment of bacterial or viral infections; keep nails trimmed to reduce bacterial colonization.
• Vaccinations: Annual influenza vaccine and other appropriate immunizations (e.g., pneumococcal) – discuss timing with your dermatologist if on biologics.
• Skin trauma avoidance: Gentle handling during shaving, nail care, or cosmetic procedures.
• Lifestyle: Balanced diet rich in omega‑3 fatty acids, regular moderate exercise, and adequate sleep.

Complications

If untreated or poorly controlled, Jennerian pustular psoriasis can lead to serious health problems.

• Sepsis: Secondary bacterial infection of ruptured pustules may progress to systemic infection.
• Electrolyte imbalances: Massive skin turnover can cause hypocalcemia, hyponatremia, and metabolic acidosis.
• Renal failure: Dehydration and nephrotoxic drugs increase risk.
• Cardiovascular strain: Persistent inflammation raises risk of myocardial infarction and stroke.
• Scarring and pigment changes: Post‑inflammatory hyperpigmentation or atrophic scarring may be permanent.
• Psychiatric morbidity: Higher rates of depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

---

Sources: Mayo Clinic; CDC; NIH – JAMA Dermatology 2020; WHO; Cleveland Clinic.